{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"40.2","value":"0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"63.2","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"Complete or partial responses were considered responses. Response was evaluated by imaging or clinical progression. The response rate (percentage of participants with responses) is reported with a 95% Blyth-Still-Casella confidence interval. Response rates are reported separately by dose level.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) received APX005M on day 1 of each 21-day course at 0.3 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG000","title":"Stratum 2, Dose Level 2"},{"description":"Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) received APX005M on day 1 of each 21-day course at 0.6 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG001","title":"Stratum 2, Dose Level 3"}],"paramType":"NUMBER","populationDescription":"Stratum 2 patients with measurable disease present at baseline who received at least one dose of therapy and had their disease re-evaluated were considered evaluable for objective response. Two participants were considered not evaluable as they did not have their disease re-evaluated.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Overall Response Rate for Stratum 2 (DIPG) Patients","type":"SECONDARY","unitOfMeasure":"percentage"}